Treatment Options for Premature Ejaculation
First-Line Pharmacological Options
- The American Urological Association recommends daily SSRI therapy as the most effective pharmacological approach for premature ejaculation, with paroxetine being the most effective, increasing ejaculatory latency 8.8-fold over baseline 1
- Daily SSRI therapy, such as sertraline 25-200 mg daily and fluoxetine 5-20 mg daily, provides consistent and stronger ejaculatory delay 2, 3
- On-demand (situational) dosing of SSRIs, such as paroxetine 20 mg taken 3-4 hours before intercourse, is also effective but provides less ejaculatory delay than daily treatment 1, 3
- Topical anesthetics, such as lidocaine/prilocaine cream, provide moderate effectiveness in delaying ejaculation, with minimal systemic effects 1, 2
Dosing Considerations
- Continuous (daily) dosing of SSRIs provides more consistent and stronger ejaculatory delay, while situational dosing may be preferred for infrequent sexual activity or patient concerns about daily medication use 1, 3
Treatment Selection Algorithm
- The treatment selection algorithm recommends daily SSRI therapy as the first choice, with paroxetine 10-20 mg daily being the most consistent option, and on-demand SSRI or clomipramine as an alternative for infrequent sexual activity 1
- Topical anesthetics are recommended for patients concerned about systemic effects, and combination therapy with daily low-dose SSRI and on-demand dosing may be considered for patients with partial response 1, 2
Important Clinical Considerations
- Patient preference and frequency of sexual activity should guide treatment choice, and psychological factors, such as anxiety, depression, and relationship issues, may contribute to premature ejaculation and should be addressed 1, 2, 3
- Psychological/behavioral therapy may be useful even when no clear psychological etiology is apparent, and patient satisfaction and quality of life should be the primary outcome measures when evaluating treatment success 1, 4
Pharmacological Treatment of Premature Ejaculation
First-Line and Alternative Therapies
- Dapoxetine 30-60 mg on-demand (1-3 hours before intercourse) is specifically approved for PE treatment in many countries, producing a 2.5-fold to 3.0-fold increase in IELT, with the 60 mg dose showing a 3.0-fold increase 5
- In men with baseline IELT <30 seconds, dapoxetine 30 mg and 60 mg result in a 3.4-fold and 4.3-fold increase in IELT, respectively 5
- Dapoxetine can be safely combined with PDE5 inhibitors, and tramadol on-demand may also be considered, with up to a 2.5-fold IELT increase, although its use should be cautious due to addiction potential and limited long-term safety data 5
- Topical lidocaine/prilocaine spray (EMA-approved formulation: lidocaine 150 mg/ml + prilocaine 50 mg/ml) increases IELT up to 6.3-fold over 3 months, with minimal systemic effects and only minor local side effects (genital hypoesthesia) 5
- Combination therapy of daily low-dose SSRI plus on-demand dosing, or SSRI plus PDE5 inhibitor, may be considered for patients with partial response to monotherapy, with the latter showing superior results to SSRI monotherapy and enhancing confidence and sexual satisfaction 5
Management Principles and Safety Considerations
- If erectile dysfunction coexists, treat ED first or concomitantly, as some acquired PE may be secondary to ED 5
- PDE5 inhibitors should not be prescribed alone to men with PE and normal erectile function, as they do not significantly improve IELT but enhance confidence and sexual satisfaction 5
- Dapoxetine discontinuation rates reach 90% at 2 years, mainly due to cost and disappointment with on-demand nature 5
Premature Ejaculation Treatment Guidelines
Introduction to Treatment Options
- Some acquired premature ejaculation may resolve when the underlying erectile dysfunction is effectively treated, as many men with erectile dysfunction develop secondary premature ejaculation due to anxiety or the need for intense stimulation to maintain erection 6
- Patient and partner satisfaction is the primary target outcome for premature ejaculation treatment, not just ejaculatory latency improvement, and treatment options should be discussed with emphasis on safety and risks 6
Pharmacological Treatment
- The American Urological Association recommends that if erectile dysfunction coexists with premature ejaculation, treat the erectile dysfunction first or concomitantly, as many men with erectile dysfunction develop secondary premature ejaculation due to anxiety or the need for intense stimulation to maintain erection 6
- None of the medications are FDA-approved specifically for premature ejaculation in the USA, so doses and dosing regimens deviate from FDA-approved indications 6
Clinical Evidence for Topical Anesthetics and Pharmacologic Strategies in Premature Ejaculation
Topical Anesthetic Therapy
- Applying lidocaine 2.5%/prilocaine 2.5% cream (EMLA) 20–30 minutes before intercourse effectively prolongs ejaculatory latency and is a suitable first‑line alternative for patients who prefer to avoid systemic medication effects. 7
- The cream may be used with or without a condom; if a condom is used, it should be removed before intercourse and the penis washed to eliminate residual anesthetic and prevent partner vaginal numbness. 7
- Prolonged application (30–45 minutes) should be avoided because excessive penile numbness can lead to loss of erection in a notable proportion of men. 7
- Residual topical anesthetic on the penis can cause vaginal numbness in the partner, which is a frequent complaint limiting the acceptability of this therapy. 7
Systemic SSRI Therapy – Common Adverse Effects
- Daily or on‑demand SSRIs used off‑label for premature ejaculation are associated with side‑effects that include ejaculation failure, decreased libido, nausea, dry mouth, insomnia, and somnolence. 7
Combination Pharmacotherapy
- Co‑administration of sildenafil (a PDE5 inhibitor) with on‑demand paroxetine enhances the ejaculatory‑delay effect of paroxetine alone, although it increases the incidence of headache and flushing. 7
Contra‑indicated or Insufficiently Supported Medications
- Phenoxybenzamine and propranolol are not recommended for premature ejaculation because current evidence does not support their efficacy. 7
Treatment Goals and Monitoring
- The primary therapeutic target is patient and partner satisfaction rather than a specific ejaculatory‑latency threshold. 7
- Treatment decisions should be guided by the reported efficacy, tolerability, and acceptance from both the patient and the partner. 7
- Clinicians should regularly reassess alternative therapeutic options and modify the regimen as needed to optimize outcomes. 7